LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received an average rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $9.25.

A number of research analysts have recently issued reports on LFMD shares. Loop Capital set a $8.00 target price on LifeMD in a report on Monday, November 24th. Lake Street Capital cut their price objective on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Mizuho reduced their target price on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, November 19th. BTIG Research dropped their target price on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, KeyCorp decreased their price target on LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 19th.

LifeMD Stock Performance

NASDAQ LFMD opened at $3.58 on Monday. LifeMD has a one year low of $3.18 and a one year high of $15.84. The firm has a market cap of $172.34 million, a PE ratio of -21.06 and a beta of 1.45. The firm’s fifty day moving average is $3.70 and its two-hundred day moving average is $5.94.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, November 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $60.17 million during the quarter, compared to analysts’ expectations of $62.07 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. Research analysts predict that LifeMD will post -0.56 earnings per share for the current year.

Insider Activity at LifeMD

In other news, CMO Jessica Friedeman sold 15,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $3.61, for a total transaction of $54,150.00. Following the transaction, the chief marketing officer directly owned 205,000 shares of the company’s stock, valued at $740,050. This represents a 6.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 18.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in LifeMD during the second quarter worth $3,828,000. Y Intercept Hong Kong Ltd purchased a new position in shares of LifeMD in the second quarter valued at $818,000. Wealthspire Advisors LLC purchased a new position in shares of LifeMD in the second quarter valued at $840,000. Jump Financial LLC raised its position in LifeMD by 205.0% during the second quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock worth $7,015,000 after acquiring an additional 346,171 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of LifeMD during the 2nd quarter worth approximately $193,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.